Publicaciones científicas

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

24-feb-2024 | Revista: Advances in Therapy

Hermann Einsele  1 , Philippe Moreau  2 , Nizar Bahlis  3 , Manisha Bhutani  4 , Laure Vincent  5 , Lionel Karlin  6 , Aurore Perrot  7 , Hartmut Goldschmidt  8 , Niels W C J van de Donk  9 , Enrique M Ocio  10 , Joaquin Martinez-Lopez  11 , Paula Rodríguez-Otero  12 , Dominik Dytfeld  13 , Joris Diels  14 , Vadim Strulev  14 , Imene Haddad  15 , Thomas Renaud  16 , Eric Ammann  17 , Jedelyn Cabrieto  14 , Nolen Perualila  14 , Ryan Gan  18 , Youyi Zhang  16 , Trilok Parekh  19 , Claire Albrecht  15 , Katja Weisel  20 , Maria-Victoria Mateos  21


Introduction: Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-world physician's choice of therapy (RWPC) was assessed using adjusted comparisons.

Methods: An external control arm for MonumenTAL-1 (subcutaneously administered talquetamab 0.4 mg/kg weekly [QW] and 0.8 mg/kg every other week [Q2W]) was created from two observational real-world studies: LocoMMotion and MoMMent. Imbalances in baseline covariates were adjusted using inverse probability weighting. The relative effectiveness of talquetamab vs. RWPC was estimated for overall response rate (ORR), ≥ very good partial response (VGPR), and ≥ complete response (CR); odds ratios and relative response ratios (RRs) were derived from weighted logistic regression. Hazard ratios (HRs) for duration of response (DOR), progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) were estimated using a weighted Cox proportional hazards model.

Results: After reweighting, baseline characteristics were balanced across cohorts. In adjusted comparisons, patients treated with talquetamab QW (n = 143) had significantly improved outcomes vs. RWPC; RRs were ORR 2.67, p < 0.0001; ≥ VGPR 4.70, p < 0.0001; ≥ CR 78.05, p = 0.0002; and HRs were PFS 0.52, p < 0.0001; TTNT 0.48, p < 0.0001; OS 0.36, p < 0.0001. Patients treated with talquetamab Q2W (n = 145) also had significantly improved outcomes vs. RWPC; RRs were ORR 2.62, p < 0.0001; ≥ VGPR 5.04, p < 0.0001; ≥ CR 101.14, p = 0.0002; and HRs were PFS 0.40, p < 0.0001; TTNT 0.39, p < 0.0001; OS 0.37, p < 0.0001.

Conclusion: Effectiveness of talquetamab for both schedules was significantly better than RWPC for ORR, ≥ VGPR, ≥ CR, PFS, OS, and TTNT, highlighting its clinical benefit for patients with TCE RRMM.

CITA DEL ARTÍCULO  Adv Ther. 2024 Feb 24. doi: 10.1007/s12325-024-02797-x

Nuestros autores